Drug intelligence / Profile preview

haishengsu

Development stage
Phase 1
Lead developer
Qingdao Haisheng Tumor Hospital
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Haishengsu (HSS) is a purified protein extract derived from the shellfish Tegillarca granosa. It has been used in traditional Chinese medicine for cancer treatment for over a century. Preclinical studies indicate that Haishengsu inhibits proliferation and induces differentiation of leukemia cells, particularly in drug-resistant cell lines such as K562/ADM and HL-60. The mechanism involves downregulation of multidrug resistance genes (mdr1), BCR/ABL, sorcin, inhibition of anti-apoptotic proteins like Bcl-2 and MPO, upregulation of pro-apoptotic Bax gene expression, increased caspase-3 activity, and reduction in p-glycoprotein levels. These effects result in enhanced apoptosis and reversal of drug resistance to agents like adriamycin. Haishengsu is currently under clinical investigation (Phase 1) for non-small cell lung cancer by Qingdao Haisheng Tumor Hospital Co., Ltd[1][6][8].

Brand names
Haishengsu Pills
Other names
Tegillarca granosa extractprotein extract from Tegillarca granosa
02

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)MPO (Myeloperoxidase)SRI (Soluble Resistance-related Calcium-binding protein)ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on haishengsu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haishengsu.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call